First-Line Use of Daratumumab in Patients with Multiple Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell Transplantation: Results from a Real-Life Single-Center Study.
autologous stem cell transplantation
daratumumab
multiple myeloma
neutrophil and platelet engraftment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
20
08
2024
revised:
20
09
2024
accepted:
25
09
2024
medline:
16
10
2024
pubmed:
16
10
2024
entrez:
16
10
2024
Statut:
epublish
Résumé
This real-life study aimed to investigate the possible impact of D-VTd induction therapy on hematopoietic engraftment after autologous stem cell transplantation (auto-SCT). Sixty consecutive NDMM patients received four cycles of induction therapy with D-VTd. The conditioning regimen consisted of melphalan 200 mg/m The median days to reach neutrophil and platelet engraftment significantly differed between patients treated with D-VTd (11 and 13 days, respectively) and VTd (10 and 12 days). Univariate Cox analyses show that patients treated with D-VTd had a hazard ratio of neutrophil engraftment that was 42% significantly lower than those in the VTd arm (HR: 0.58, Our real-life study showed that a four-drug induction therapy containing DARA does not impact transplant safety outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
This real-life study aimed to investigate the possible impact of D-VTd induction therapy on hematopoietic engraftment after autologous stem cell transplantation (auto-SCT).
METHODS
METHODS
Sixty consecutive NDMM patients received four cycles of induction therapy with D-VTd. The conditioning regimen consisted of melphalan 200 mg/m
RESULTS
RESULTS
The median days to reach neutrophil and platelet engraftment significantly differed between patients treated with D-VTd (11 and 13 days, respectively) and VTd (10 and 12 days). Univariate Cox analyses show that patients treated with D-VTd had a hazard ratio of neutrophil engraftment that was 42% significantly lower than those in the VTd arm (HR: 0.58,
CONCLUSIONS
CONCLUSIONS
Our real-life study showed that a four-drug induction therapy containing DARA does not impact transplant safety outcomes.
Identifiants
pubmed: 39409927
pii: cancers16193307
doi: 10.3390/cancers16193307
pii:
doi:
Types de publication
Journal Article
Langues
eng